134 related articles for article (PubMed ID: 25749380)
21. MicroRNA-130b functions as a tumor suppressor by regulating RUNX3 in epithelial ovarian cancer.
Paudel D; Zhou W; Ouyang Y; Dong S; Huang Q; Giri R; Wang J; Tong X
Gene; 2016 Jul; 586(1):48-55. PubMed ID: 27048832
[TBL] [Abstract][Full Text] [Related]
22. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic accuracy of peripheral blood Kisspeptin mRNA and plasma CA125 protein for detection of epithelial ovarian cancer in patients who have ever been pregnant.
Chen L; Liu M; Ji J; Lin W; Shan F; Liu H
Neoplasma; 2016; 63(6):999-1006. PubMed ID: 27596301
[TBL] [Abstract][Full Text] [Related]
24. The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer.
Zuberi M; Khan I; Gandhi G; Ray PC; Saxena A
Tumour Biol; 2016 Aug; 37(8):11259-66. PubMed ID: 26951510
[TBL] [Abstract][Full Text] [Related]
25. PRSS3 expression is associated with tumor progression and poor prognosis in epithelial ovarian cancer.
Ma R; Ye X; Cheng H; Ma Y; Cui H; Chang X
Gynecol Oncol; 2015 Jun; 137(3):546-52. PubMed ID: 25735255
[TBL] [Abstract][Full Text] [Related]
26. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
28. miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
Ge G; Zhang W; Niu L; Yan Y; Ren Y; Zou Y
Oncol Rep; 2016 Mar; 35(3):1816-22. PubMed ID: 26676658
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L
Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797
[TBL] [Abstract][Full Text] [Related]
30. Integrated microRNA and mRNA signatures in peripheral blood lymphocytes of familial epithelial ovarian cancer.
Dou YD; Huang T; Wang Q; Shu X; Zhao SG; Li L; Liu T; Lu G; Chan WY; Liu HB
Biochem Biophys Res Commun; 2018 Jan; 496(1):191-198. PubMed ID: 29307835
[TBL] [Abstract][Full Text] [Related]
31. HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma.
Mahajan A; Liu Z; Gellert L; Zou X; Yang G; Lee P; Yang X; Wei JJ
Mod Pathol; 2010 May; 23(5):673-81. PubMed ID: 20228781
[TBL] [Abstract][Full Text] [Related]
32. AEG -1 overexpression: a novel indicator for peritoneal dissemination and lymph node metastasis in epithelial ovarian cancers.
Li C; Liu J; Lu R; Yu G; Wang X; Zhao Y; Song H; Lin P; Sun X; Yu X; Zhang Y; Ning X; Geng J
Int J Gynecol Cancer; 2011 May; 21(4):602-8. PubMed ID: 21543927
[TBL] [Abstract][Full Text] [Related]
33. Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
Sun F; Ding W; He JH; Wang XJ; Ma ZB; Li YF
BMC Cancer; 2015 Oct; 15():746. PubMed ID: 26487491
[TBL] [Abstract][Full Text] [Related]
34. Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC).
Rohr I; Braicu EI; En-Nia A; Heinrich M; Richter R; Chekerov R; Dechend R; Heidecke H; Dragun D; Schäfer R; Gorny X; Lindquist JA; Brandt S; Sehouli J; Mertens PR
Cytokine; 2016 Sep; 85():157-64. PubMed ID: 27371774
[TBL] [Abstract][Full Text] [Related]
35. High-mobility group A2 overexpression is an unfavorable prognostic biomarker for nasopharyngeal carcinoma patients.
Liu Z; Wu K; Yang Z; Wu A
Mol Cell Biochem; 2015 Nov; 409(1-2):155-62. PubMed ID: 26183485
[TBL] [Abstract][Full Text] [Related]
36. Differential MicroRNA Expression Profiles in Primary and Recurrent Epithelial Ovarian Cancer.
Chong GO; Jeon HS; Han HS; Son JW; Lee YH; Hong DG; Lee YS; Cho YL
Anticancer Res; 2015 May; 35(5):2611-7. PubMed ID: 25964536
[TBL] [Abstract][Full Text] [Related]
37. MiR-219-5p inhibits growth and metastasis of ovarian cancer cells by targeting HMGA2.
Xing F; Song Z; He Y
Biol Res; 2018 Nov; 51(1):50. PubMed ID: 30474570
[TBL] [Abstract][Full Text] [Related]
38. Formyl peptide receptor 2 expression predicts poor prognosis and promotes invasion and metastasis in epithelial ovarian cancer.
Xie X; Yang M; Ding Y; Yu L; Chen J
Oncol Rep; 2017 Dec; 38(6):3297-3308. PubMed ID: 29039544
[TBL] [Abstract][Full Text] [Related]
39. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
Zuberi M; Mir R; Das J; Ahmad I; Javid J; Yadav P; Masroor M; Ahmad S; Ray PC; Saxena A
Clin Transl Oncol; 2015 Oct; 17(10):779-87. PubMed ID: 26063644
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA‑455 inhibits cell proliferation and invasion of epithelial ovarian cancer by directly targeting Notch1.
Xu L; Li H; Su L; Lu Q; Liu Z
Mol Med Rep; 2017 Dec; 16(6):9777-9785. PubMed ID: 29039517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
